RESUMEN
AIMS: To engineer and screen a novel GLP-1/anti-apolipoprotein B (apoB) bifunctional fusion protein with therapeutic potential on alleviating diabetes and diabetic complication in combination with low-intensity ultrasound. MAIN METHODS: Anti-apoB antibodies were screened by phage display technology and further fused to mutated GLP-1 (7-37) via light or heavy fusion to generate bifunctional fusion protein (termed aBG). The optimal design of aBG fusion protein was further confirmed by in vitro epitope competition assay and cAMP accumulation assay. Subsequently, chronic study in DIO mice were subjected to assess the long-term efficacy of screened fusion protein. KEY FINDINGS: The selected GLP-1/anti-apoB fusion protein, aBG-8, exerted either the highest binding affinities for GLP-1R and apoB, or the greatest LDL-C uptake capacity and GLP-1R activation activity. After 60-day treatment in DIO mice, aBG-8 was proved to exert the promising improvement on hyperglycemia, hyperlipidemia, and obesity in DIO mice. Furthermore, combined therapy of aBG-8 and low-intensity ultrasound could accelerate skin wound closure in diabetic mice. SIGNIFICANCE: A novel long-lasting bifunctional fusion molecule, aBG-8, was designed with the enormous potential on alleviating diabetes and diabetic complications in combination with low-intensity ultrasound.
Asunto(s)
Anticuerpos/uso terapéutico , Apolipoproteínas B/antagonistas & inhibidores , Complicaciones de la Diabetes/terapia , Diabetes Mellitus/terapia , Péptido 1 Similar al Glucagón/uso terapéutico , Terapia por Ultrasonido , Animales , Células CHO , Cricetulus , Complicaciones de la Diabetes/patología , Diabetes Mellitus/patología , Diabetes Mellitus Experimental/patología , Diabetes Mellitus Experimental/terapia , Células Hep G2 , Humanos , Masculino , Ratones Endogámicos C57BL , Proteínas Recombinantes de Fusión/uso terapéutico , Terapia por Ultrasonido/métodosRESUMEN
Drugs reducing plasma concentrations of apolipoprotein B-containing lipoproteins have been demonstrated to reduce the risk of cardiovascular disease (CVD) in both primary and secondary prevention. Despite the demonstrated efficacy of statins and ezetimibe on low-density lipoprotein (LDL) concentration and long-term CVD risk, a large number of patients do not achieve their therapeutic goals. The introduction of monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) protein was a milestone in the treatment of lipid disorders, as their administration leads to unprecedentedly low LDL cholesterol concentrations. Inclisiran represents an entirely new mechanism of PSCK9 protein inhibition in hepatocytes, targeting the messenger RNA for PCSK9. Its administration is necessary only every 3 to 6 months, which is an essential advantage over statin and monoclonal antibody therapy. The infrequent administration regimen can increase the number of patients who maintain their therapeutic goals, especially in patients struggling to comply with daily or biweekly pharmacotherapy. Preclinical studies and Phase I and Phase II clinical trials of inclisiran have demonstrated its tolerability and efficacy in promoting long-term reduction of both PCSK9 protein and LDL cholesterol. The efficacy and safety of inclisiran will continue to be assessed in ongoing and forthcoming trials on larger patient groups. If the results of these trials reflect previously published data, they will add further evidence that inclisiran might be a revolutionary new tool in the pharmacologic management of plasma lipids. This review summarizes the currently available literature data on inclisiran with respect to its mechanism of action, effectiveness, and safety as a lipid-lowering drug for CVD prevention.
Asunto(s)
Apolipoproteínas B/genética , Trastornos del Metabolismo de los Lípidos/tratamiento farmacológico , Proproteína Convertasa 9/genética , ARN Interferente Pequeño/uso terapéutico , Apolipoproteínas B/antagonistas & inhibidores , Apolipoproteínas B/sangre , LDL-Colesterol/sangre , LDL-Colesterol/genética , Ezetimiba/antagonistas & inhibidores , Ezetimiba/uso terapéutico , Hepatocitos/efectos de los fármacos , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/efectos adversos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Trastornos del Metabolismo de los Lípidos/sangre , Trastornos del Metabolismo de los Lípidos/metabolismo , Inhibidores de PCSK9RESUMEN
We herein report a new approach for RNA interference, so-called "build-up RNAi" approach, where single-strand circular RNAs with a photocleavable unit or disulfide moiety were used as siRNA precursors. The advantages of using these circular RNA formats for RNAi were presented in aspects of immunogenicity and cellular uptake.
Asunto(s)
Interferencia de ARN , Precursores del ARN/química , ARN Circular/química , ARN Interferente Pequeño/química , Apolipoproteínas B/antagonistas & inhibidores , Apolipoproteínas B/genética , Apolipoproteínas B/metabolismo , Precursores del ARN/síntesis química , Precursores del ARN/efectos de la radiación , ARN Circular/síntesis química , ARN Interferente Pequeño/metabolismo , Rayos UltravioletaRESUMEN
PURPOSE OF REVIEW: High lipoprotein(a) levels are observationally and causally, from human genetics, associated with increased risk of cardiovascular disease including myocardial infarction and aortic valve stenosis. The European Atherosclerosis Society recommends screening for elevated lipoprotein(a) levels in high-risk patients. Different therapies have been suggested and some are used to treat elevated lipoprotein(a) levels such as niacin, PCSK9 inhibitors, and CETP inhibitors; however, to date, no randomized controlled trial has demonstrated that lowering of lipoprotein(a) leads to lower risk of cardiovascular disease. RECENT FINDINGS: Synthetic oligonucleotides can be used to inactivate genes involved in disease processes. To lower lipoprotein(a), two antisense oligonucleotides have been developed, one targeting apolipoprotein B and one targeting apolipoprotein(a). Mipomersen is an antisense oligonucleotide targeting apolipoprotein B and thereby reducing levels of all apolipoprotein B containing lipoproteins in the circulation. Mipomersen has been shown to lower lipoprotein(a) by 20-50% in phase 3 studies. AKCEA-APO(a)-LRx is the most recent antisense oligonucleotide targeting apolipoprotein(a) and thereby uniquely targeting lipoprotein(a). It has been tested in a phase 2 study and has shown to lower lipoprotein(a) levels by 50-80%. The treatment of elevated lipoprotein(a) levels with the newest antisense oligonucleotides seems promising; however, no improvement in cardiovascular disease risk has yet been shown. However, a phase 3 study of AKCEA-APO(a)-LRx is being planned with cardiovascular disease as outcome, and results are awaited with great anticipation.
Asunto(s)
Apoproteína(a)/antagonistas & inhibidores , Hiperlipoproteinemias/tratamiento farmacológico , Oligodesoxirribonucleótidos Antisentido/farmacología , Oligodesoxirribonucleótidos Antisentido/uso terapéutico , Oligonucleótidos/farmacología , Oligonucleótidos/uso terapéutico , Anticuerpos Monoclonales/farmacología , Anticuerpos Monoclonales/uso terapéutico , Apolipoproteínas B/antagonistas & inhibidores , Aterosclerosis/prevención & control , Proteínas de Transferencia de Ésteres de Colesterol/antagonistas & inhibidores , Humanos , Inhibidores de PCSK9 , Interferencia de ARNRESUMEN
Efforts to chemically modify nucleic acids got underway merely a decade after the discovery of the DNA double helix and initially targeted nucleosides and nucleotides. The origins of three analogues that remain staples of modification strategies and figure prominently in FDA-approved nucleic acid therapeutics can be traced to the 1960s: 2'-deoxy-2'-fluoro-RNA (2'-F RNA), 2'- O-methyl-RNA (2'- OMe RNA), and the phosphorothioates (PS-DNA/RNA). Progress in nucleoside phosphoramidite-based solid phase oligonucleotide synthesis has gone hand in hand with the creation of second-generation (e.g., 2'- O-(2-methoxyethyl)-RNA, MOE-RNA) and third-generation (e.g., bicyclic nucleic acids, BNAs) analogues, giving rise to an expanding universe of modified nucleic acids. Thus, beyond site-specifically altered DNAs and RNAs with a modified base, sugar, and/or phosphate backbone moieties, nucleic acid chemists have created a host of conjugated oligonucleotides and artificial genetic polymers (XNAs). The search for oligonucleotides with therapeutic efficacy constitutes a significant driving force for these investigations. However, nanotechnology, diagnostics, synthetic biology and genetics, nucleic acid etiology, and basic research directed at the properties of native and artificial pairing systems have all stimulated the design of ever more diverse modifications. Modification of nucleic acids can affect pairing and chemical stability, conformation and interactions with a flurry of proteins and enzymes that play important roles in uptake, transport or processing of targets. Enhancement of metabolic stability is a central concern in the design of antisense, siRNA and aptamer oligonucleotides for therapeutic applications. In the antisense approach, uniformly modified oligonucleotides or so-called gapmers are used to target a specific RNA. The former may sterically block transcription or direct alternative splicing, whereas the latter feature a central PS window that elicits RNase H-mediated cleavage of the target. The key enzyme in RNA interference (RNAi) is Argonaute 2 (Ago2), a dynamic multidomain enzyme that binds multiple regions of the guide (antisense) and passenger (sense) siRNAs. The complexity of the individual interactions between Ago2 and the siRNA duplex provides significant challenges for chemical modification. Therefore, a uniform (the same modification throughout, e.g., antisense) or nearly uniform (e.g., aptamer) modification strategy is less useful in the pursuit of siRNA therapeutic leads. Instead, unique structural features and protein interactions of 5'-end (guide/Ago2MID domain), seed region, central region (cleavage site/Ago2 PIWI domain), and 3'-terminal nucleotides (guide/Ago2 PAZ domain) demand a more nuanced approach in the design of chemically modified siRNAs for therapeutic use. This Account summarizes current siRNA modification strategies with an emphasis on the regio-specific interactions between oligonucleotide and Ago2 and how these affect the choice of modification and optimization of siRNA efficacy. In addition to standard assays applied to measure the effects of modification on the stability of pairing and resistance against nuclease degradation, structural insights based on crystallographic data for modified RNAs alone and in complex with Ago2 from molecular modeling studies are a valuable guide in the design of siRNA therapeutics. Thus, this comprehensive approach is expected to result in accelerated generation of new siRNA-based therapies against various diseases, now that the first siRNA has obtained approval by the US FDA for treatment of hereditary hATTR amyloidosis.
Asunto(s)
ARN Interferente Pequeño/química , ARN/metabolismo , Apolipoproteínas B/antagonistas & inhibidores , Apolipoproteínas B/metabolismo , Proteínas Argonautas/antagonistas & inhibidores , Proteínas Argonautas/genética , Proteínas Argonautas/metabolismo , Humanos , Hipercolesterolemia/tratamiento farmacológico , Modelos Moleculares , Conformación de Ácido Nucleico , Oligonucleótidos/química , Oligonucleótidos/metabolismo , Oligonucleótidos/uso terapéutico , Dominios Proteicos , ARN/química , Interferencia de ARN , ARN Interferente Pequeño/metabolismo , ARN Interferente Pequeño/uso terapéutico , Ribonucleasas/metabolismoRESUMEN
Recently, some studies have reported nephrotoxicity associated with a certain class of antisense oligonucleotides (ASOs) in humans. One possibility for reducing the potential nephrotoxicity of ASOs is to alter their pharmacokinetics. In this study, we investigated the effect of a ligand conjugation strategy on the renal accumulation of ASOs. We selected two ligands, cholesterol and N-acetylgalactosamine (GalNAc), with the purpose of reducing renal distribution and liver targeting, and then designed a series of cholesterol-GalNAc dual conjugated ASOs. The gene-silencing activity of the cholesterol-GalNAc dual conjugated ASO in the liver was slightly lower than that of a GalNAc-conjugated ASO. On the other hand, the renal distribution of the cholesterol-GalNAc dual conjugated ASO was considerably decreased compared with the GalNAc-conjugated ASO, as we expected. As dual conjugation was successful in reducing the renal distribution of ASO, it should be an effective strategy for reducing the nephrotoxic potential of ASOs.
Asunto(s)
Acetilgalactosamina/química , Colesterol/química , Silenciador del Gen , Riñón/metabolismo , Hígado/metabolismo , Oligonucleótidos Antisentido/farmacocinética , Animales , Apolipoproteínas B/antagonistas & inhibidores , Apolipoproteínas B/genética , Apolipoproteínas B/metabolismo , Receptor de Asialoglicoproteína/genética , Receptor de Asialoglicoproteína/metabolismo , Secuencia de Carbohidratos , Ligandos , Masculino , Ratones , Ratones Endogámicos C57BL , Oligonucleótidos Antisentido/química , Oligonucleótidos Antisentido/genética , Unión Proteica , Distribución TisularRESUMEN
Many factors enter into the decision by the Food and Drug Administration (FDA) to approve a new drug for use by physicians and other health care providers in treating diseases. Initially, the FDA authority was restricted to issues of safety and only later did the documentation of efficacy become part of the review process required for approval. However, all drugs have the potential for causing harm at some dose level to all and at lower doses in certain patients with vulnerability to the particular pharmacology of the agent. As new drugs have been designed to manage disorders that are uncommon, but of significant consequence, they may have adverse effects that are acceptable only because they are so uniquely beneficial to these specific conditions. The risk of these adverse effects may be acceptable since the benefit can outweigh the harm in most patients and the adversity can be predicted and managed. The approval of this category of drugs has grown rapidly since definition of a mechanism of action to manage and modify the risk has been provided by a process known as known as Risk Evaluation and Mitigation Strategy or "REMS." In 2007, the Food and Drug Administration Amendments Act (FDAAA) allowed the FDA to require postmarketing studies and the authority to mandate the implementation of a REMS for drugs with efficacy but documented potential for harm. Two relatively new drugs useful in the management of severe elevations of low-density lipoprotein cholesterol have been approved under a requirement for a REMS. These are lomitapide, an inhibitor of microsomal triglyceride transfer protein and mipomersen, an antisense oligonucleotide which reduces the synthesis of apolipoprotein B.
Asunto(s)
Anticolesterolemiantes/efectos adversos , Anticolesterolemiantes/uso terapéutico , Apolipoproteínas B/antagonistas & inhibidores , Apolipoproteínas B/genética , Apolipoproteínas B/metabolismo , Bencimidazoles/efectos adversos , Bencimidazoles/uso terapéutico , Proteínas Portadoras/antagonistas & inhibidores , Proteínas Portadoras/metabolismo , LDL-Colesterol/sangre , Aprobación de Drogas , Humanos , Hipercolesterolemia/tratamiento farmacológico , Oligonucleótidos/efectos adversos , Oligonucleótidos/uso terapéutico , Medición de Riesgo , Estados Unidos , United States Food and Drug AdministrationRESUMEN
Oats are a rich source of ß-glucan, a viscous, soluble fibre recognised for its cholesterol-lowering properties, and are associated with reduced risk of CVD. Our objective was to conduct a systematic review and meta-analysis of randomised-controlled trials (RCT) investigating the cholesterol-lowering potential of oat ß-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for the risk reduction of CVD. MEDLINE, Embase, CINAHL and Cochrane CENTRAL were searched. We included RCT of ≥3 weeks of follow-up, assessing the effect of diets enriched with oat ß-glucan compared with controlled diets on LDL-cholesterol, non-HDL-cholesterol or apoB. Two independent reviewers extracted data and assessed study quality and risk of bias. Data were pooled using the generic inverse-variance method with random effects models and expressed as mean differences with 95 % CI. Heterogeneity was assessed by the Cochran's Q statistic and quantified by the I 2-statistic. In total, fifty-eight trials (n 3974) were included. A median dose of 3·5 g/d of oat ß-glucan significantly lowered LDL-cholesterol (-0·19; 95 % CI -0·23, -0·14 mmol/l, P<0·00001), non-HDL-cholesterol (-0·20; 95 % CI -0·26, -0·15 mmol/l, P<0·00001) and apoB (-0·03; 95 % CI -0·05, -0·02 g/l, P<0·0001) compared with control interventions. There was evidence for considerable unexplained heterogeneity in the analysis of LDL-cholesterol (I 2=79 %) and non-HDL-cholesterol (I 2=99 %). Pooled analyses showed that oat ß-glucan has a lowering effect on LDL-cholesterol, non-HDL-cholesterol and apoB. Inclusion of oat-containing foods may be a strategy for achieving targets in CVD reduction.
Asunto(s)
Anticolesterolemiantes/uso terapéutico , Avena/química , Enfermedades Cardiovasculares/prevención & control , Suplementos Dietéticos , Medicina Basada en la Evidencia , Hipercolesterolemia/dietoterapia , beta-Glucanos/uso terapéutico , Anticolesterolemiantes/administración & dosificación , Anticolesterolemiantes/química , Apolipoproteínas B/antagonistas & inhibidores , Apolipoproteínas B/sangre , Biomarcadores/sangre , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Colesterol/sangre , Colesterol/química , HDL-Colesterol/agonistas , HDL-Colesterol/sangre , LDL-Colesterol/antagonistas & inhibidores , LDL-Colesterol/sangre , Fibras de la Dieta/administración & dosificación , Fibras de la Dieta/uso terapéutico , Alimentos Funcionales , Humanos , Hipercolesterolemia/sangre , Hipercolesterolemia/fisiopatología , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto , Riesgo , Semillas/química , Solubilidad , beta-Glucanos/administración & dosificación , beta-Glucanos/químicaRESUMEN
Small interfering RNA (siRNA)-mediated silencing requires siRNA loading into the RNA-induced silencing complex (RISC). Presence of 5'-phosphate (5'-P) is reported to be critical for efficient RISC loading of the antisense strand (AS) by anchoring it to the mid-domain of the Argonaute2 (Ago2) protein. Phosphorylation of exogenous duplex siRNAs is thought to be accomplished by cytosolic Clp1 kinase. However, although extensive chemical modifications are essential for siRNA-GalNAc conjugate activity, they can significantly impair Clp1 kinase activity. Here, we further elucidated the effect of 5'-P on the activity of siRNA-GalNAc conjugates. Our results demonstrate that a subset of sequences benefit from the presence of exogenous 5'-P. For those that do, incorporation of 5'-(E)-vinylphosphonate (5'-VP), a metabolically stable phosphate mimic, results in up to 20-fold improved in vitro potency and up to a threefold benefit in in vivo activity by promoting Ago2 loading and enhancing metabolic stability.
Asunto(s)
Acetilgalactosamina/química , Organofosfonatos/química , Interferencia de ARN , ARN Interferente Pequeño/química , Compuestos de Vinilo/química , Animales , Apolipoproteínas B/antagonistas & inhibidores , Apolipoproteínas B/genética , Apolipoproteínas B/metabolismo , Proteínas Argonautas/antagonistas & inhibidores , Proteínas Argonautas/genética , Proteínas Argonautas/metabolismo , Células Cultivadas , Factor IX/antagonistas & inhibidores , Factor IX/genética , Factor IX/metabolismo , Hepatocitos/citología , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Humanos , Lipoproteínas LDL/sangre , Ratones , Ratones Endogámicos C57BL , Organofosfonatos/farmacología , ARN Interferente Pequeño/metabolismo , Proteínas de Unión al ARN , Complejo Silenciador Inducido por ARN/química , Complejo Silenciador Inducido por ARN/metabolismo , Factores de Transcripción/metabolismo , Compuestos de Vinilo/farmacologíaRESUMEN
An efficient targeting delivery technology is needed for functional oligonucleotides to exert their potential effect on the target gene without an adverse effect in vivo. Development of enteral delivery systems for nucleic acids is a major challenge because of their large molecular size and instability. Here, we describe a new enteral delivery technique that enables small interfering RNA (siRNA) selectively delivered to the liver to silence its target Apolipoprotein B gene expression. A nuclease-resistant synthetic siRNA was conjugated with α-tochopherol and administered as lipid nanoparticle to the large intestine of the mice in a postprandial state. The selective transport into the liver, effective gene silence, and consequently significant reduction in serum low density lipoprotein-cholesterol level, were demonstrated. The chylomicron-mediated pathway via the lymphatic route was suggested as major mechanism. This unique approach may provide a basis for developing oral and rectal delivery systems for nucleic acids targeting liver.
Asunto(s)
Apolipoproteínas B/antagonistas & inhibidores , Sistemas de Liberación de Medicamentos/métodos , Silenciador del Gen , Nanopartículas/administración & dosificación , Compuestos Organofosforados/administración & dosificación , ARN Interferente Pequeño/genética , Administración Rectal , Animales , Apolipoproteínas B/genética , Apolipoproteínas B/metabolismo , Transporte Biológico , Quilomicrones/sangre , Yeyuno/efectos de los fármacos , Yeyuno/metabolismo , Lipoproteínas LDL/sangre , Hígado/efectos de los fármacos , Hígado/metabolismo , Vasos Linfáticos/fisiología , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos ICR , Nanopartículas/química , Nanopartículas/metabolismo , Compuestos Organofosforados/química , Compuestos Organofosforados/metabolismo , Periodo Posprandial/fisiología , ARN Interferente Pequeño/administración & dosificación , ARN Interferente Pequeño/metabolismo , alfa-Tocoferol/administración & dosificación , alfa-Tocoferol/química , alfa-Tocoferol/metabolismoRESUMEN
UNLABELLED: Hepatitis C virus (HCV) infects hepatocytes through two different routes: (i) cell-free particle diffusion followed by engagement with specific cellular receptors and (ii) cell-to-cell direct transmission mediated by mechanisms not well defined yet. HCV exits host cells in association with very-low-density lipoprotein (VLDL) components. VLDL particles contain apolipoproteins B (ApoB) and E (ApoE), which are required for viral assembly and/or infectivity. Based on these precedents, we decided to study whether these VLDL components participate in HCV cell-to-cell transmission in vitro. We observed that cell-to-cell viral spread was compromised after ApoE interference in donor but not in acceptor cells. In contrast, ApoB knockdown in either donor or acceptor cells did not impair cell-to-cell viral transmission. Interestingly, ApoB participated in the assembly of cell-free infective virions, suggesting a differential regulation of cell-to-cell and cell-free HCV infection. This study identifies host-specific factors involved in these distinct routes of infection that may unveil new therapeutic targets and advance our understanding of HCV pathogenesis. IMPORTANCE: This work demonstrates that cell-to-cell transmission of HCV depends on ApoE but not ApoB. The data also indicate that ApoB is required for the assembly of cell-free infective particles, strongly suggesting the existence of mechanisms involving VLDL components that differentially regulate cell-free and cell-to-cell HCV transmission. These data clarify some of the questions regarding the role of VLDL in HCV pathogenesis and the transmission of the virus cell to cell as a possible mechanism of immune evasion and open the door to therapeutic intervention.
Asunto(s)
Apolipoproteínas B/metabolismo , Apolipoproteínas E/metabolismo , Hepacivirus/patogenicidad , Hepatitis C/transmisión , Hepatocitos/metabolismo , Hepatocitos/virología , Apolipoproteínas B/antagonistas & inhibidores , Apolipoproteínas B/genética , Apolipoproteínas E/antagonistas & inhibidores , Apolipoproteínas E/genética , Línea Celular , Sistema Libre de Células , Técnicas de Silenciamiento del Gen , Hepacivirus/genética , Hepacivirus/fisiología , Hepatitis C/metabolismo , Hepatitis C/virología , Interacciones Huésped-Patógeno/fisiología , Humanos , Lipoproteínas VLDL/metabolismo , Modelos Biológicos , Ensamble de Virus/fisiologíaRESUMEN
Mipomersen (Kynamro(®)), a second-generation 2'-O-methoxyethyl chimeric antisense oligonucleotide (ASO), inhibits the synthesis of apolipoprotein B (apoB) and is indicated in the US as an adjunct therapy for homozygous familial hypercholesterolemia (HoFH) at a dose of 200 mg subcutaneously (SC) once weekly. The pharmacokinetic (PK) properties of mipomersen are generally consistent across all species studied, including mouse, rat, monkey, and humans. After SC administration, mipomersen is rapidly and extensively absorbed. It has an apparent plasma and tissue terminal elimination half-life of approximately 30 days. Mipomersen achieves steady-state tissue concentrations within approximately 4-6 months of once-weekly dosing. It does not exhibit PK-based drug-drug interactions with other concomitant medications, either involving competition for plasma protein binding or alterations in disposition of any evaluated drugs. Furthermore, mipomersen does not prolong the corrected QT (QTc) interval. There have been no ethnic- or gender-related differences in PK observed. In clinical trials, both as a single agent and in the presence of maximal lipid-lowering therapy, mipomersen has demonstrated significant dose-dependent reductions in all measured apoB-containing atherogenic lipoproteins. Overall, mipomersen has well-characterized PK and pharmacodynamic properties in both animals and humans, and is an efficacious adjunct treatment for patients with HoFH.
Asunto(s)
Anticolesterolemiantes/farmacología , Apolipoproteínas B/antagonistas & inhibidores , Oligonucleótidos/farmacología , Oligonucleótidos/farmacocinética , Animales , Anticolesterolemiantes/química , Anticolesterolemiantes/farmacocinética , Secuencia de Bases , Ensayos Clínicos como Asunto , Humanos , Hiperlipoproteinemia Tipo I/tratamiento farmacológico , Hiperlipoproteinemia Tipo I/metabolismo , Modelos Moleculares , Oligodesoxirribonucleótidos Antisentido/farmacocinética , Oligodesoxirribonucleótidos Antisentido/farmacología , Oligonucleótidos/químicaRESUMEN
Second-generation antisense oligonucleotides (ASOs) demonstrate excellent biological stability and in vitro/in vivo potency, and thus are considered to be attractive candidates for drugs to treat various diseases. A pharmacokinetic-pharmacodynamic (PK-PD) model of ASOs is desired for the design of appropriate PK and pharmacological studies. The objective of this study was to develop a PK-PD model to accurately simulate hepatic ASO concentration and its efficacy from plasma ASO concentration. After single subcutaneous administration of an ASO targeting hepatic apolipoprotein B (Apo-B) mRNA to mice, the ASO was absorbed rapidly and showed biphasic decline with time from the plasma and liver (t1/2: 1-3 and 81-183 h, Tmax: 0.25-0.50 and 4-8 h). After administration, hepatic Apo-B mRNA and plasma total cholesterol began decreasing at 4-8 and 8-24 h, and their Tmax values were observed at 24-72 and 72 h. To develop the PK-PD model based on the mechanisms of ASOs, we described the plasma and hepatic ASO concentration with linear two-compartment models. In addition, we inserted two indirect response models for mRNA and plasma total cholesterol. Model predictions from plasma ASO concentration gave excellent fits to the observed values of hepatic ASO concentration, Apo-B mRNA and plasma total cholesterol after single or multiple subcutaneous administrations. Our PK-PD model could accurately predict hepatic ASO concentrations and their efficacies from plasma ASO concentrations. This PK-PD model could be a useful tool for suggesting PK and pharmacological study protocols for various liver-targeted second-generation ASOs.
Asunto(s)
Apolipoproteínas B/antagonistas & inhibidores , Colesterol/sangre , Hígado , Modelos Biológicos , Oligonucleótidos Antisentido/farmacología , Oligonucleótidos Antisentido/farmacocinética , ARN Mensajero/antagonistas & inhibidores , Animales , Apolipoproteína B-100 , Simulación por Computador , Femenino , Hígado/efectos de los fármacos , Hígado/metabolismo , Ratones Endogámicos C57BL , Oligonucleótidos Antisentido/sangre , Factores de TiempoAsunto(s)
Anticolesterolemiantes/administración & dosificación , Bencimidazoles/administración & dosificación , Proteínas Portadoras/antagonistas & inhibidores , LDL-Colesterol/antagonistas & inhibidores , Hígado Graso/patología , Hiperlipoproteinemia Tipo II/tratamiento farmacológico , Animales , Anticolesterolemiantes/efectos adversos , Apolipoproteínas B/antagonistas & inhibidores , Apolipoproteínas B/sangre , Bencimidazoles/efectos adversos , Transporte Biológico , Eliminación de Componentes Sanguíneos , Proteínas Portadoras/metabolismo , LDL-Colesterol/sangre , Hígado Graso/etiología , Hígado Graso/metabolismo , Humanos , Hiperlipoproteinemia Tipo II/sangre , Hiperlipoproteinemia Tipo II/patología , Ratones , Microsomas/efectos de los fármacos , Microsomas/metabolismo , Triglicéridos/antagonistas & inhibidores , Triglicéridos/sangreRESUMEN
Lipid nanoparticles (LNPs) represent the most clinically advanced technology for the systemic delivery of therapeutic siRNA in vivo. Toward this end, a novel class of LNPs comprising low molecular weight (MW) ionizable amino lipids having asymmetric architecture was recently reported.1 LNPs of these amino lipids, termed asymmetric LNPs, were shown to be highly efficacious and well tolerated in vivo; advances were enabled by improved endosomal escape, coupled with enhanced amino lipid metabolism and clearance. In this work, we show that, in contrast to their desirable pharmacological performance, asymmetric LNPs present a significant pharmaceutical developability challenge, namely physical instability limiting extended shelf life. Using orthogonal characterization methods, we identify the mechanism of LNP instability as Ostwald ripening and establish it to be driven predominantly by the asymmetric amino lipid component. Through rational optimization of LNP physical and macromolecular properties, we are able to significantly attenuate or entirely eliminate the Ostwald ripening instability. Modulation of LNP size, for example, effectively halts particle growth. Similarly, optimization of LNP macromolecular packing through deliberate selection of structurally matched colipids significantly diminishes the rate of ripening. This later experimental observation is substantiated by molecular dynamics simulations of LNP self-assembly, which establish a quantitative dependence of LNP macromolecular order on colipid structure. In totality, the experimental and molecular dynamics outcomes of this work support the rational design of LNP physical and chemical properties leading to effective Ostwald ripening stabilization and enable the advance of asymmetric LNPs as a clinic-ready platform for siRNA therapeutics.
Asunto(s)
Aminoácidos/química , Apolipoproteínas B/antagonistas & inhibidores , Sistemas de Liberación de Medicamentos , Lípidos/química , Nanopartículas/química , ARN Interferente Pequeño/administración & dosificación , Animales , Apolipoproteínas B/genética , Cromatografía en Gel , Femenino , Microscopía Electrónica de Transmisión , Simulación de Dinámica Molecular , Peso Molecular , Tamaño de la Partícula , ARN Mensajero/antagonistas & inhibidores , ARN Mensajero/genética , ARN Interferente Pequeño/genética , Ratas , Ratas Sprague-Dawley , Propiedades de SuperficieAsunto(s)
Bencimidazoles/uso terapéutico , LDL-Colesterol/sangre , Homocigoto , Hiperlipoproteinemia Tipo II/tratamiento farmacológico , Hiperlipoproteinemia Tipo II/genética , Oligonucleótidos/uso terapéutico , Anticolesterolemiantes/efectos adversos , Anticolesterolemiantes/uso terapéutico , Apolipoproteínas B/antagonistas & inhibidores , Bencimidazoles/efectos adversos , Proteínas Portadoras/antagonistas & inhibidores , Relación Dosis-Respuesta a Droga , Humanos , Hiperlipoproteinemia Tipo II/sangre , Oligonucleótidos/efectos adversos , Resultado del Tratamiento , Estados Unidos , United States Food and Drug AdministrationRESUMEN
OBJECTIVES: This study sought to examine the efficacy and safety of mipomersen for reducing atherogenic lipids and lipoproteins in patients with hypercholesterolemia. BACKGROUND: Many patients on lipid-lowering therapies remain unable to achieve target low-density lipoprotein (LDL) cholesterol levels. Mipomersen, an antisense oligonucleotide inhibitor of apolipoprotein B, reduces LDL cholesterol and atherogenic lipoproteins. METHODS: This randomized, double-blind, multicenter study enrolled 158 patients with baseline LDL cholesterol levels ≥100 mg/dl with, or at high risk for, coronary heart disease who were receiving maximally tolerated lipid-lowering therapy. Patients received weekly subcutaneous mipomersen 200 mg (n = 105) or placebo (n = 52) for 26 weeks, with a 24-week follow-up period. Randomization was stratified by type 2 diabetes status. RESULTS: Sixty mipomersen and 44 placebo patients completed treatment. Mean baseline LDL cholesterol levels were 122.7 and 122.6 mg/dl in the placebo and mipomersen patients, respectively. Mipomersen reduced LDL cholesterol by -36.9% compared with placebo at -4.5% (p < 0.001). Target LDL cholesterol <100 mg/dl was attained in 76% of mipomersen and 38% of placebo patients. Mipomersen also significantly reduced apolipoprotein B (-38%) and lipoprotein(a) (-24%) (p < 0.001). Common adverse events included injection site reactions (78% with mipomersen, 31% with placebo) and flu-like symptoms (34% with mipomersen, 21% with placebo). Elevations in transaminases and liver fat also occurred in some patients, and these levels returned toward baseline after treatment cessation. CONCLUSIONS: Mipomersen significantly reduced LDL cholesterol, apolipoprotein B, and lipoprotein(a) in patients with hypercholesterolemia with, or at risk for, coronary heart disease not controlled by existing therapies. (Safety and Efficacy of Mipomersen [ISIS 301012] as Add-On Therapy in High Risk Hypercholesterolemic Patients; NCT00770146).
Asunto(s)
Anticolesterolemiantes/uso terapéutico , Apolipoproteínas B/antagonistas & inhibidores , Aterosclerosis/prevención & control , Enfermedades Cardiovasculares/prevención & control , LDL-Colesterol/sangre , Hipercolesterolemia/tratamiento farmacológico , Oligonucleótidos/uso terapéutico , Adulto , Anciano , Anticolesterolemiantes/administración & dosificación , Anticolesterolemiantes/farmacología , LDL-Colesterol/efectos de los fármacos , Método Doble Ciego , Esquema de Medicación , Femenino , Humanos , Hipercolesterolemia/sangre , Hiperlipoproteinemia Tipo II/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Oligonucleótidos/administración & dosificación , Oligonucleótidos/farmacología , Medición de Riesgo , Factores de Riesgo , Resultado del TratamientoAsunto(s)
Anticolesterolemiantes/uso terapéutico , Apolipoproteínas B/antagonistas & inhibidores , Aterosclerosis/prevención & control , Enfermedades Cardiovasculares/prevención & control , LDL-Colesterol/sangre , Hipercolesterolemia/tratamiento farmacológico , Oligonucleótidos/uso terapéutico , Femenino , Humanos , MasculinoRESUMEN
BACKGROUND: Reduction in plasma low-density lipoprotein cholesterol (LDL-C) is a fundamental treatment for the prevention of acute coronary syndromes (ACS). Although statin therapy confers significant protection against ACS in both primary and secondary prevention, a considerable residual risk remains after intensive therapy. In addition, a significant proportion of high-risk patients do not achieve the optimal LDL-C goal recommended in the current guidelines (<1.8 mmol/L). Hence, novel LDL-C-lowering agents that act via mechanisms distinct from HMG-CoA reductase inhibition are under investigation. OBJECTIVE: We reviewed the recent literature on the development of novel LDL-C-lowering agents that could potentially be used as an alternative or adjunct to statin therapy in high-risk coronary patients. METHODS: PubMed and Scopus databases were searched to retrieve studies on the efficacy and/or tolerability of novel LDL-C-lowering agents in animals and humans. RESULTS: Agents that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein (apo) B, and microsomal triglyceride transfer protein (MTTP) are the most promising therapies. Inhibition of PCSK9, apoB, and MTTP has been achieved mostly via fully humanized monoclonal antibodies (mAbs), antisense oligonucleotides, and synthetic compounds, respectively. PCSK9 inhibitors increase the hepatic uptake of LDL-C, while apoB and MTTP inhibitors decrease the synthesis and secretion of apoB-containing lipoproteins. These 3 mechanisms lead to marked reductions in plasma LDL-C in patients with hypercholesterolemia at risk for ACS, particularly those with familial hypercholesterolemia. Moreover, these agents can exert additional benefits by decreasing plasma levels of apoB, triglycerides, and lipoprotein(a). Mipomersen and lomitapide have been approved by the United States Food and Drug Administration (US FDA) for use in patients with homozygous familial hypercholesterolemia. PCSK9 inhibitors are currently under final evaluation in clinical outcomes studies and are anticipated to find wide application either as monotherapy or as an adjunct to statins. A main safety concern is the risk for hepatic steatosis with apoB and MTTP inhibitors, which needs to be explored in prospective, long-term trials. CONCLUSIONS: PCSK9, apoB, and MTTP inhibitors can exert potent reductions in plasma LDL-C and apoB concentrations, either as monotherapy or in combination with statins. These effects are particularly relevant to high-risk individuals with marked hypercholesterolemia, such as those with familial hypercholesterolemia. Although the use of mipomersen and lomitapide is limited to severe familial hypercholesterolemia as a replacement for LDL-apheresis, PCSK9 inhibitors are likely to be more widely prescribed in patients at high risk for CVD, especially those who are resistant to or intolerant of high-intensity statin therapy. PCSK9 mAbs are efficacious and have an excellent safety profile, but their long-term impact on cardiovascular events is currently under investigation. Whether PCSK9 mAbs decrease the rates of recurrent cardiovascular events within 3 months following ACS is questionable; however, these agents, unlike statins, may not have pleiotropic benefits on the unstable plaque.
Asunto(s)
Síndrome Coronario Agudo/prevención & control , Anticolesterolemiantes/uso terapéutico , LDL-Colesterol/sangre , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Animales , Anticuerpos Monoclonales/farmacología , Anticuerpos Monoclonales/uso terapéutico , Anticolesterolemiantes/efectos adversos , Anticolesterolemiantes/farmacología , Apolipoproteínas B/antagonistas & inhibidores , Apolipoproteínas B/genética , Apolipoproteínas B/metabolismo , Proteínas Portadoras/antagonistas & inhibidores , Proteínas Portadoras/metabolismo , Ensayos Clínicos como Asunto , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/efectos adversos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Hipercolesterolemia/tratamiento farmacológico , Oligonucleótidos Antisentido/efectos adversos , Oligonucleótidos Antisentido/farmacología , Oligonucleótidos Antisentido/uso terapéutico , Proproteína Convertasa 9 , Proproteína Convertasas/antagonistas & inhibidores , Proproteína Convertasas/genética , Proproteína Convertasas/metabolismo , Serina Endopeptidasas/genética , Serina Endopeptidasas/metabolismoRESUMEN
It is now appreciated that over 90% of the human genome is comprised of noncoding RNAs that have the ability to affect other components of the genome and regulate gene expression. This has galvanized the development of RNA-based therapeutics for a myriad of diseases, including cancer, inflammatory conditions, and cardiovascular disease. Several classes of RNA therapeutics are currently under clinical development, including antisense oligonucleotides, small interfering RNA, and microRNA mimetics and inhibitors. The field of antisense technology saw a huge leap forward with the recent Food and Drug Administration approval of the first antisense therapy, directed against apolipoprotein B, for the treatment of familial hypercholesterolemia. In addition, recent progress in the development of approaches to inhibit microRNAs has helped to illuminate their roles in repressing gene networks and also revealed their potential as therapeutic targets. In this review, these exciting opportunities in the field of drug discovery, with a focus on emerging therapeutics in the field of cardiovascular disease, are summarized.